|
DE69836877D1
(de)
|
1997-07-22 |
2007-02-22 |
Shionogi & Co |
Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie
|
|
BR9810841A
(pt)
|
1997-07-31 |
2001-07-10 |
Procter & Gamble |
Inibidores de metaloprotease alicìclicos
|
|
IL127496A0
(en)
*
|
1997-12-19 |
1999-10-28 |
Pfizer Prod Inc |
The use of MMP inhibitors for the treatment of ocular angiogenesis
|
|
EP1918278A1
(en)
|
1998-02-04 |
2008-05-07 |
Novartis AG |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
US6410580B1
(en)
|
1998-02-04 |
2002-06-25 |
Novartis Ag |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
US6075136A
(en)
*
|
1998-02-17 |
2000-06-13 |
Incyte Pharmaceuticals, Inc. |
Prostate-associated serine protease
|
|
US6492394B1
(en)
|
1998-12-22 |
2002-12-10 |
Syntex (U.S.A.) Llc |
Sulfonamide hydroxamates
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
BR0007784A
(pt)
|
1999-01-27 |
2002-02-05 |
American Cyanamid Co |
Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
MXPA01008855A
(es)
|
1999-03-03 |
2002-07-02 |
Procter & Gamble |
Inhibidores de metaloproteasa que contienen alquenilo y alquinilo.
|
|
HK1044935A1
(zh)
|
1999-03-03 |
2002-11-08 |
The Procter & Gamble Company |
双异取代的金属蛋白酶抑制剂
|
|
US6696456B1
(en)
*
|
1999-10-14 |
2004-02-24 |
The Procter & Gamble Company |
Beta disubstituted metalloprotease inhibitors
|
|
CN1610661A
(zh)
|
2001-11-01 |
2005-04-27 |
惠氏控股公司 |
用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
CA2471814C
(en)
|
2001-12-27 |
2011-03-15 |
Sumitomo Pharmaceuticals Co., Ltd. |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
|
EP2428509A1
(en)
|
2002-06-12 |
2012-03-14 |
Symphony Evolution, Inc. |
Human adam-10 inhibitors
|
|
WO2005021489A2
(en)
|
2002-12-23 |
2005-03-10 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
|
US20090018094A1
(en)
*
|
2006-12-01 |
2009-01-15 |
Loma Linda University Medical Center |
Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
|
|
WO2020070239A1
(en)
|
2018-10-04 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|